Bcl2/bcl-xL inhibitor engenders apoptosis and increases chemosensitivity in mesothelioma

Xiaobo Cao, Charles Rodarte, Lidong Zhang, Clinton D. Morgan, James E Littlejohn, W. Roy Smythe

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Meosthelioma is a neoplasm of the pleura that is currently incurable by conventional therapies. Previously, we demonstrated that mesothelioma overexpresses BCL-XL, an anti-apoptotic member of the BCL-2 family. In addition, we have shown that downregulation of BCL-XL using a BCL-XL antisense oligonucleotide engenders mesothelioma apoptotic cell death in vitro and in vivo. The purpose of this study is to evaluate the efficacy of bcl2/bcl-xL inhibitor, 2-methoxy antimycin A3, in inducing apoptosis and increasing chemo-sensitivity in vitro and in vivo. Several bcl-xL high-expression tumor cell lines and one normal human cell line were exposed to 2-methoxy antimycin A3. 2-methoxy antimycin A3 demonstrated significant growth inhibition only in these tumor cell lines, with little effect on normal human cells. Treatment with 2-methoxy antimycin A3 alone resulted in a dramatic increase in the induction of apoptosis in the cancer cells. Apoptosis occurs through decreasing mitochondrial membrane potential and caspase activation. Notably, treatment with 2-methoxy antimycin A3 does not alter BCL-2 family protein expression. Synergistic inhibition of tumor growth by the coadministration of cisplatin and 2-methoxy antimycin A3 was observed in both in vitro and in vivo experiments. Together, these findings indicate that exposure of cancer cells to small molecule Bcl-2/xL inhibitors such as 2-methoxy antimycin A3 alone, or in the combination with other chemotherapeutics, may represent a novel therapeutic strategy in treatment of cancer, especially mesothelioma.

Original languageEnglish (US)
Pages (from-to)246-252
Number of pages7
JournalCancer Biology and Therapy
Volume6
Issue number2
StatePublished - Feb 2007
Externally publishedYes

Fingerprint

Mesothelioma
Apoptosis
Neoplasms
Tumor Cell Line
Pleura
Antisense Oligonucleotides
Mitochondrial Membrane Potential
Growth
Caspases
2-methoxyantimycin
Cisplatin
Cell Death
Down-Regulation
Cell Line
Therapeutics
In Vitro Techniques
Proteins

Keywords

  • 2-methoxy antimycin A3
  • Animal model
  • Apoptosis
  • Bcl-x
  • BH3 peptide
  • Chemotherapy
  • Mesothelioma
  • Mitochondrial membrane potential
  • Small-molecule inhibitor
  • Synergy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cao, X., Rodarte, C., Zhang, L., Morgan, C. D., Littlejohn, J. E., & Smythe, W. R. (2007). Bcl2/bcl-xL inhibitor engenders apoptosis and increases chemosensitivity in mesothelioma. Cancer Biology and Therapy, 6(2), 246-252.

Bcl2/bcl-xL inhibitor engenders apoptosis and increases chemosensitivity in mesothelioma. / Cao, Xiaobo; Rodarte, Charles; Zhang, Lidong; Morgan, Clinton D.; Littlejohn, James E; Smythe, W. Roy.

In: Cancer Biology and Therapy, Vol. 6, No. 2, 02.2007, p. 246-252.

Research output: Contribution to journalArticle

Cao, X, Rodarte, C, Zhang, L, Morgan, CD, Littlejohn, JE & Smythe, WR 2007, 'Bcl2/bcl-xL inhibitor engenders apoptosis and increases chemosensitivity in mesothelioma', Cancer Biology and Therapy, vol. 6, no. 2, pp. 246-252.
Cao, Xiaobo ; Rodarte, Charles ; Zhang, Lidong ; Morgan, Clinton D. ; Littlejohn, James E ; Smythe, W. Roy. / Bcl2/bcl-xL inhibitor engenders apoptosis and increases chemosensitivity in mesothelioma. In: Cancer Biology and Therapy. 2007 ; Vol. 6, No. 2. pp. 246-252.
@article{fda18ff782d5436991a86db526d36e9c,
title = "Bcl2/bcl-xL inhibitor engenders apoptosis and increases chemosensitivity in mesothelioma",
abstract = "Meosthelioma is a neoplasm of the pleura that is currently incurable by conventional therapies. Previously, we demonstrated that mesothelioma overexpresses BCL-XL, an anti-apoptotic member of the BCL-2 family. In addition, we have shown that downregulation of BCL-XL using a BCL-XL antisense oligonucleotide engenders mesothelioma apoptotic cell death in vitro and in vivo. The purpose of this study is to evaluate the efficacy of bcl2/bcl-xL inhibitor, 2-methoxy antimycin A3, in inducing apoptosis and increasing chemo-sensitivity in vitro and in vivo. Several bcl-xL high-expression tumor cell lines and one normal human cell line were exposed to 2-methoxy antimycin A3. 2-methoxy antimycin A3 demonstrated significant growth inhibition only in these tumor cell lines, with little effect on normal human cells. Treatment with 2-methoxy antimycin A3 alone resulted in a dramatic increase in the induction of apoptosis in the cancer cells. Apoptosis occurs through decreasing mitochondrial membrane potential and caspase activation. Notably, treatment with 2-methoxy antimycin A3 does not alter BCL-2 family protein expression. Synergistic inhibition of tumor growth by the coadministration of cisplatin and 2-methoxy antimycin A3 was observed in both in vitro and in vivo experiments. Together, these findings indicate that exposure of cancer cells to small molecule Bcl-2/xL inhibitors such as 2-methoxy antimycin A3 alone, or in the combination with other chemotherapeutics, may represent a novel therapeutic strategy in treatment of cancer, especially mesothelioma.",
keywords = "2-methoxy antimycin A3, Animal model, Apoptosis, Bcl-x, BH3 peptide, Chemotherapy, Mesothelioma, Mitochondrial membrane potential, Small-molecule inhibitor, Synergy",
author = "Xiaobo Cao and Charles Rodarte and Lidong Zhang and Morgan, {Clinton D.} and Littlejohn, {James E} and Smythe, {W. Roy}",
year = "2007",
month = "2",
language = "English (US)",
volume = "6",
pages = "246--252",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "2",

}

TY - JOUR

T1 - Bcl2/bcl-xL inhibitor engenders apoptosis and increases chemosensitivity in mesothelioma

AU - Cao, Xiaobo

AU - Rodarte, Charles

AU - Zhang, Lidong

AU - Morgan, Clinton D.

AU - Littlejohn, James E

AU - Smythe, W. Roy

PY - 2007/2

Y1 - 2007/2

N2 - Meosthelioma is a neoplasm of the pleura that is currently incurable by conventional therapies. Previously, we demonstrated that mesothelioma overexpresses BCL-XL, an anti-apoptotic member of the BCL-2 family. In addition, we have shown that downregulation of BCL-XL using a BCL-XL antisense oligonucleotide engenders mesothelioma apoptotic cell death in vitro and in vivo. The purpose of this study is to evaluate the efficacy of bcl2/bcl-xL inhibitor, 2-methoxy antimycin A3, in inducing apoptosis and increasing chemo-sensitivity in vitro and in vivo. Several bcl-xL high-expression tumor cell lines and one normal human cell line were exposed to 2-methoxy antimycin A3. 2-methoxy antimycin A3 demonstrated significant growth inhibition only in these tumor cell lines, with little effect on normal human cells. Treatment with 2-methoxy antimycin A3 alone resulted in a dramatic increase in the induction of apoptosis in the cancer cells. Apoptosis occurs through decreasing mitochondrial membrane potential and caspase activation. Notably, treatment with 2-methoxy antimycin A3 does not alter BCL-2 family protein expression. Synergistic inhibition of tumor growth by the coadministration of cisplatin and 2-methoxy antimycin A3 was observed in both in vitro and in vivo experiments. Together, these findings indicate that exposure of cancer cells to small molecule Bcl-2/xL inhibitors such as 2-methoxy antimycin A3 alone, or in the combination with other chemotherapeutics, may represent a novel therapeutic strategy in treatment of cancer, especially mesothelioma.

AB - Meosthelioma is a neoplasm of the pleura that is currently incurable by conventional therapies. Previously, we demonstrated that mesothelioma overexpresses BCL-XL, an anti-apoptotic member of the BCL-2 family. In addition, we have shown that downregulation of BCL-XL using a BCL-XL antisense oligonucleotide engenders mesothelioma apoptotic cell death in vitro and in vivo. The purpose of this study is to evaluate the efficacy of bcl2/bcl-xL inhibitor, 2-methoxy antimycin A3, in inducing apoptosis and increasing chemo-sensitivity in vitro and in vivo. Several bcl-xL high-expression tumor cell lines and one normal human cell line were exposed to 2-methoxy antimycin A3. 2-methoxy antimycin A3 demonstrated significant growth inhibition only in these tumor cell lines, with little effect on normal human cells. Treatment with 2-methoxy antimycin A3 alone resulted in a dramatic increase in the induction of apoptosis in the cancer cells. Apoptosis occurs through decreasing mitochondrial membrane potential and caspase activation. Notably, treatment with 2-methoxy antimycin A3 does not alter BCL-2 family protein expression. Synergistic inhibition of tumor growth by the coadministration of cisplatin and 2-methoxy antimycin A3 was observed in both in vitro and in vivo experiments. Together, these findings indicate that exposure of cancer cells to small molecule Bcl-2/xL inhibitors such as 2-methoxy antimycin A3 alone, or in the combination with other chemotherapeutics, may represent a novel therapeutic strategy in treatment of cancer, especially mesothelioma.

KW - 2-methoxy antimycin A3

KW - Animal model

KW - Apoptosis

KW - Bcl-x

KW - BH3 peptide

KW - Chemotherapy

KW - Mesothelioma

KW - Mitochondrial membrane potential

KW - Small-molecule inhibitor

KW - Synergy

UR - http://www.scopus.com/inward/record.url?scp=34247336873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247336873&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 246

EP - 252

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 2

ER -